Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience

  • Kourie, Hampig Raphael (Hematology-Oncology Department, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Rassy, Marc (Pathology Department, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Ghorra, Claude (Pathology Department, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Naderi, Samah (Pathology Department, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University) ;
  • Kattan, Joseph (Hematology-Oncology Department, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University)
  • Published : 2015.09.02


Background: To compare the current histologic distribution of lung cancer in Lebanon to the worldwide trends, according to the 2004 WHO Classification. Materials and Methods: 1,760 patients with a pulmonary pathology examination at Hotel-Dieu de France University Hospital between July 2009 and July 2014 were included. Results: Some 676 out of the total investigated patients (38.4%) had a lung tumor. In 665 (98.4%) the tumors were malignant, with a mean age at diagnosis of 63.8 years and a male/female (M/F) sex ratio of 1.7:1. Among the malignant tumors, 86.2% were epithelial tumors with a mean age at diagnosis of 64.8 years and an M/F sex ratio of 1.9. Other malignant tumors consisted of metastatic tumors (10.2%), lymphoproliferative tumors (2.1%) and mesenchymal tumors (1.5%). Most common carcinoma subtypes were adenocarcinoma (48.0%), squamous cell carcinoma (23.0%) and small cell carcinoma (13.3%). Carcinoid tumors were the only carcinoma subtype with an M/F sex ratio below 1 (0.7). Salivary gland tumors were the carcinoma with lowest mean age at diagnosis (45.5 years). Conclusions: The histologic distribution of lung tumors in Lebanon is similar to that in developed countries. We believe this resemblance is due to common smoking habits, known to be responsible for the increase of lung adenocarcinoma at the expense of other subtypes.


  1. Demirci E, Daloglu F, Gundogdu C, et al (2013). Incidence and clinicopathologic features of primary lung cancer: a North- Eastern Anatolia region study in Turkey (2006-2012). Asian Pac J Cancer Prev, 14, 1989-93.
  2. Dey A, Biswas D, Saha SK, et al (2012). Comparison study of clinicoradiological profile of primary lung cancer cases: an Eastern India experience. Indian J Cancer, 49, 89-95.
  3. El-Basmy A (2013). Profile of lung cancer in kuwait. Asian Pac J Cancer Prev, 14, 6181-4.
  4. Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, 359-86.
  5. Hainsworth JD, Fang L, Huang JE, et al (2011). BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol, 6, 109-14.
  6. Hajmanoochehri F, Mohammadi N, Zohal MA, et al (2014). Epidemiological and clinicopathological characteristics of lung cancer in a teaching hospital in Iran. Asian Pac J Cancer Prev, 15, 2495-500.
  7. Houston KA, Henley SJ, Li J, et al (2014). Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer, 86, 22-8.
  8. Inoue M, Okumura M, Sawabata N, et al (2014). Clinicopathological characteristics and surgical results of lung cancer patients aged up to 50 years: the Japanese Lung Cancer Registry Study 2004. Lung Cancer, 83, 246-51.
  9. Kong J, Xu F, He M, et al (2014). The incidence of lung cancer by histological type: a population-based study in Tianjin, China during 1981-2005. Respirol, 19, 1222-8.
  10. Lee PN, Forey BA, Coombs KJ (2012). Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer, 12, 385.
  11. Lewis DR, Check DP, Caporaso NE, et al (2014). US lung cancer trends by histologic type. Cancer, 120, 2883-92.
  12. Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al (2014). International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer, 84, 13-22.
  13. Mitchell PL, Thursfield VJ, Ball DL, et al (2013). Lung cancer in Victoria: are we making progress? Med J Aust, 199, 674-9.
  14. National Cancer Registry [Online] (2008). Beirut: Ministry of Public Health.
  15. Quoix E, Lemarie E (2011). [Epidemiological novelties in lung cancer]. Rev Mal Respir, 28, 1048-58.
  16. Sagerup CM, Smastuen M, Johannesen TB, et al (2012). Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients. J Thorac Oncol, 7, 57-63.
  17. Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51.
  18. Spitz MR, Gorlov IP, Amos CI, et al (2011). Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discov, 1, 420-9.
  19. Wang J, Wu N, Zheng Q, et al (2014). Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution. J Cancer Res Clin Oncol, 140, 1189-95.
  20. Yang P (2011). Lung cancer in never smokers. Semin Respir Crit Care Med, 32, 10-21.
  21. Yang SC, Lai WW, Su WC, et al (2013). Estimating the lifelong health impact and financial burdens of different types of lung cancer. BMC Cancer, 13, 579.
  22. Yenugadhati N, Birkett NJ, Momoli F, et al (2009). Occupations and lung cancer: a population-based case-control study in British Columbia. J Toxicol Environ Health A, 72, 658-75.